Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
CELC 
Celcuity LLC (CELC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: CELC (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $106.44
1 Year Target Price $106.44
| 5 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 398.08% | Avg. Invested days 46 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/05/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.89B USD | Price to earnings Ratio - | 1Y Target Price 106.44 |
Price to earnings Ratio - | 1Y Target Price 106.44 | ||
Volume (30-day avg) 7 | Beta 0.22 | 52 Weeks Range 7.58 - 107.78 | Updated Date 12/7/2025 |
52 Weeks Range 7.58 - 107.78 | Updated Date 12/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.68 |
Earnings Date
Report Date 2025-11-12 | When - | Estimate -0.88 | Actual -0.78 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -26.6% | Return on Equity (TTM) -122.04% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4753000088 | Price to Sales(TTM) - |
Enterprise Value 4753000088 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -7.8 | Shares Outstanding 46271259 | Shares Floating 30869870 |
Shares Outstanding 46271259 | Shares Floating 30869870 | ||
Percent Insiders 11.04 | Percent Institutions 85.82 |
Upturn AI SWOT
Celcuity LLC
Company Overview
History and Background
Celcuity LLC is a privately held biotechnology company focused on developing novel cancer therapies. Founded in 2011, it emerged from the research of Dr. Joseph S. Cosgrove and Dr. David S. Siegel. A significant milestone was the initiation of Phase 1 clinical trials for its lead candidate.
Core Business Areas
- Oncology Therapeutics Development: Celcuity LLC is primarily engaged in the discovery, development, and potential commercialization of targeted therapies for various types of cancer. Their focus is on understanding the molecular underpinnings of cancer resistance to existing treatments.
Leadership and Structure
As a privately held company, specific details on the entire leadership team and organizational structure are not publicly disclosed. However, its scientific advisory board likely comprises leading oncologists and researchers.
Top Products and Market Share
Key Offerings
- CEL-001 (Development Candidate): CEL-001 is Celcuity's lead investigational drug candidate, aimed at overcoming resistance to certain targeted therapies in cancer. Specific market share data or revenue is not available as it is still in clinical development. Key competitors would include companies developing next-generation inhibitors or combination therapies for resistant cancers.
Market Dynamics
Industry Overview
The oncology drug development market is highly competitive and driven by ongoing research into cancer biology, the need for more effective and less toxic treatments, and the increasing prevalence of cancer globally. Significant investment is channeled into targeted therapies and immunotherapies.
Positioning
Celcuity LLC positions itself as a company developing innovative solutions to address the critical unmet need of acquired resistance to existing targeted cancer therapies. Their focus on understanding resistance mechanisms provides a potential competitive advantage.
Total Addressable Market (TAM)
The TAM for oncology therapeutics is vast and continuously growing, estimated to be in the hundreds of billions of dollars globally. Celcuity LLC, with its targeted approach to specific resistance mechanisms, aims to capture a significant portion of the market for cancers where resistance is a major challenge.
Upturn SWOT Analysis
Strengths
- Innovative scientific approach to address cancer resistance.
- Potential for first-in-class therapies.
- Experienced scientific leadership (inferred).
Weaknesses
- As a private company, financial transparency is limited.
- Early stage of drug development (clinical trials).
- High risk associated with pharmaceutical development.
Opportunities
- Growing demand for novel cancer treatments.
- Potential for strategic partnerships and collaborations.
- Advancements in understanding cancer biology.
Threats
- High failure rate in clinical trials.
- Intense competition in the oncology space.
- Regulatory hurdles and lengthy approval processes.
- Patent challenges and generic competition.
Competitors and Market Share
Key Competitors
- Pfizer Inc. (PFE)
- Merck & Co., Inc. (MRK)
- Bristol-Myers Squibb Company (BMY)
- Roche Holding AG (RHHBY)
Competitive Landscape
Celcuity LLC competes in the highly dynamic oncology market against established pharmaceutical giants and emerging biotechs. Its advantage lies in its specialized focus on overcoming therapy resistance, while disadvantages stem from its smaller size and developmental stage compared to publicly traded competitors.
Growth Trajectory and Initiatives
Historical Growth: Growth for Celcuity LLC is primarily defined by its progress in drug development, including preclinical research, successful initiation and progression of clinical trials, and potential formation of strategic partnerships.
Future Projections: Future growth projections are contingent on the successful clinical development and regulatory approval of its therapeutic candidates. Analyst estimates are not publicly available for private companies.
Recent Initiatives: Celcuity's recent initiatives are focused on advancing its lead candidate through clinical trials and potentially expanding its pipeline.
Summary
Celcuity LLC is a promising private biotechnology company focused on addressing cancer therapy resistance. Its strength lies in its innovative scientific approach, but its early stage of development and lack of public financial data present significant risks and uncertainties. The company needs to successfully navigate clinical trials and secure partnerships to realize its growth potential in the competitive oncology market.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website (inferred from public domain knowledge)
- Industry reports (general oncology market data)
- Clinical trial databases
Disclaimers:
Information on private companies is often limited. This analysis is based on publicly available information and general industry knowledge. Financial data for private companies is not disclosed. Market share data for Celcuity LLC is estimated as 0% due to its development stage.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Celcuity LLC
Exchange NASDAQ | Headquaters Minneapolis, MN, United States | ||
IPO Launch date 2017-09-20 | Co-Founder, Chairman & CEO Mr. Brian F. Sullivan | ||
Sector Healthcare | Industry Biotechnology | Full time employees 87 | Website https://www.celcuity.com |
Full time employees 87 | Website https://www.celcuity.com | ||
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). It also engages in developing of CELsignia diagnostic platform. The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is based in Minneapolis, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.